RPRX
NASDAQ · Pharmaceuticals
Royalty Pharma Plc- Cl A
$67.57
+0.01 (+0.01%)
Financial Highlights (FY 2026)
Revenue
2.43B
Net Income
787.88M
Gross Margin
—
Profit Margin
32.4%
Rev Growth
+2.1%
D/E Ratio
1.38
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 54.8% | 54.8% |
| Operating Margin | 65.6% | 59.0% | 15.6% | 14.4% |
| Profit Margin | 32.4% | 30.8% | 14.1% | 12.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.43B | 2.38B | 6.69B | 7.54B |
| Gross Profit | — | — | 3.67B | 4.13B |
| Operating Income | 1.59B | 1.41B | 1.05B | 1.08B |
| Net Income | 787.88M | 694.78M | 946.13M | 901.52M |
| Gross Margin | — | — | 54.8% | 54.8% |
| Operating Margin | 65.6% | 59.0% | 15.6% | 14.4% |
| Profit Margin | 32.4% | 30.8% | 14.1% | 12.0% |
| Rev Growth | +2.1% | +2.1% | +2.6% | +1.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 11.24B | 11.24B | 4.82B | 4.40B |
| Total Equity | 8.13B | 8.13B | 11.63B | 12.28B |
| D/E Ratio | 1.38 | 1.38 | 0.41 | 0.36 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 1.59B | 1.48B | 1.13B | 1.39B |
| Free Cash Flow | — | — | 700.09M | 771.28M |